BiOneCure Therapeutics LLC is a biotechnology company committed to the discovery and development of innovative biotherapeutics for the treatment of cancer. The company is developing novel bispecific antibodies and a new class of antibody-drug conjugates (ADCs). Bispecific antibodies combine specificities of two different antibodies and are able to target two different antigens or epitopes simultaneously. ADCs are tumor-targeting antibodies chemically conjugated to a highly potent cytotoxic agent (warheads). Bispecific antibodies and ADCs promise huge potential for cancer therapy. A series of novel cytotoxic warheads being developed by BiOneCure feature new mechanisms of action for tumor cell killing and inhibition, which will enhance the therapeutic application and the safety of ADCs in clinical treatment of cancer patients. The company was founded in 2016 by industrial veterans and is based in Germantown, Maryland.